399 related articles for article (PubMed ID: 27877031)
1. The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study.
Wang CY; Lai CC; Yang WC; Lin CC; Chen L; Wang HC; Yu CJ
Int J Chron Obstruct Pulmon Dis; 2016; 11():2775-2783. PubMed ID: 27877031
[TBL] [Abstract][Full Text] [Related]
2. Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist.
Yang HH; Lai CC; Wang YH; Yang WC; Wang CY; Wang HC; Chen L; Yu CJ
Int J Chron Obstruct Pulmon Dis; 2017; 12():2477-2485. PubMed ID: 28860742
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
Perrone V; Sangiorgi D; Buda S; Degli Esposti L
Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.
Cheng SL; Lin CH
Int J Chron Obstruct Pulmon Dis; 2016; 11():2341-2348. PubMed ID: 27703344
[TBL] [Abstract][Full Text] [Related]
5. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.
Kern DM; Davis J; Williams SA; Tunceli O; Wu B; Hollis S; Strange C; Trudo F
Respir Res; 2015 Apr; 16(1):52. PubMed ID: 25899176
[TBL] [Abstract][Full Text] [Related]
7. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD.
Janson C; Stratelis G; Miller-Larsson A; Harrison TW; Larsson K
Int J Chron Obstruct Pulmon Dis; 2017; 12():3055-3064. PubMed ID: 29089754
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Risk of Pneumonia Caused by Fluticasone Propionate versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study.
Choi JH; Jeong KB; Park YH; Yu I; Lee SJ; Lee MK; Kim SH; Lee WY; Yong SJ; Lee JH
Int J Chron Obstruct Pulmon Dis; 2021; 16():3229-3237. PubMed ID: 34858023
[TBL] [Abstract][Full Text] [Related]
9. Effect of outpatient therapy with inhaled corticosteroids on decreasing in-hospital mortality from pneumonia in patients with COPD.
Yamauchi Y; Yasunaga H; Hasegawa W; Sakamoto Y; Takeshima H; Jo T; Matsui H; Fushimi K; Nagase T
Int J Chron Obstruct Pulmon Dis; 2016; 11():1403-11. PubMed ID: 27382276
[TBL] [Abstract][Full Text] [Related]
10. Comparative Safety and Effectiveness of Inhaled Corticosteroid and Long-Acting β
Chang TY; Chien JY; Wu CH; Dong YH; Lin FJ
Chest; 2020 May; 157(5):1117-1129. PubMed ID: 31887282
[TBL] [Abstract][Full Text] [Related]
11. Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists.
Wang CY; Lin YS; Wang YH; Lai CC; Wang HC; Chen L; Yu CJ;
Aging (Albany NY); 2019 Sep; 11(17):6863-6871. PubMed ID: 31509517
[TBL] [Abstract][Full Text] [Related]
12. Risk of pneumonia with budesonide-containing treatments in COPD: an individual patient-level pooled analysis of interventional studies.
Hollis S; Jorup C; Lythgoe D; Martensson G; Regnell P; Eckerwall G
Int J Chron Obstruct Pulmon Dis; 2017; 12():1071-1084. PubMed ID: 28435240
[TBL] [Abstract][Full Text] [Related]
13. Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids.
Huang TM; Kuo KC; Wang YH; Wang CY; Lai CC; Wang HC; Chen L; Yu CJ;
BMC Infect Dis; 2020 Sep; 20(1):706. PubMed ID: 32977747
[TBL] [Abstract][Full Text] [Related]
14. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
[TBL] [Abstract][Full Text] [Related]
15. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
[TBL] [Abstract][Full Text] [Related]
16. Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial.
Tashkin DP; Miravitlles M; Celli BR; Metzdorf N; Mueller A; Halpin DMG; Anzueto A
Respir Res; 2018 Oct; 19(1):196. PubMed ID: 30290801
[TBL] [Abstract][Full Text] [Related]
17. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of nonvertebral fractures among patients with COPD in the UK General Practice Research Database.
Miller DP; Watkins SE; Sampson T; Davis KJ
Phys Sportsmed; 2010 Dec; 38(4):19-27. PubMed ID: 21150138
[TBL] [Abstract][Full Text] [Related]
18. Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies.
Lodise TP; Li J; Gandhi HN; O'Brien G; Sethi S
Int J Chron Obstruct Pulmon Dis; 2020; 15():2889-2900. PubMed ID: 33204085
[TBL] [Abstract][Full Text] [Related]
19. Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan.
Hirano R; Fujita M; Matsumoto T; On R; Watanabe K
Int J Chron Obstruct Pulmon Dis; 2018; 13():3503-3509. PubMed ID: 30498340
[TBL] [Abstract][Full Text] [Related]
20. Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study.
Morjaria JB; Rigby A; Morice AH
Lung; 2017 Jun; 195(3):281-288. PubMed ID: 28255905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
